| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes.
|
Blood
|
2009
|
23.52
|
|
2
|
Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia.
|
N Engl J Med
|
2009
|
10.54
|
|
3
|
Ancestry and pharmacogenomics of relapse in acute lymphoblastic leukemia.
|
Nat Genet
|
2011
|
4.93
|
|
4
|
Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children's oncology group study.
|
J Clin Oncol
|
2009
|
4.20
|
|
5
|
Identification of novel cluster groups in pediatric high-risk B-precursor acute lymphoblastic leukemia with gene expression profiling: correlation with genome-wide DNA copy number alterations, clinical characteristics, and outcome.
|
Blood
|
2010
|
4.00
|
|
6
|
Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG).
|
Blood
|
2006
|
3.91
|
|
7
|
The genomic landscape of hypodiploid acute lymphoblastic leukemia.
|
Nat Genet
|
2013
|
3.43
|
|
8
|
Absolute lymphocyte counts refine minimal residual disease-based risk stratification in childhood acute lymphoblastic leukemia.
|
Pediatr Blood Cancer
|
2011
|
3.13
|
|
9
|
Gene expression classifiers for relapse-free survival and minimal residual disease improve risk classification and outcome prediction in pediatric B-precursor acute lymphoblastic leukemia.
|
Blood
|
2009
|
2.86
|
|
10
|
Genome-wide interrogation of germline genetic variation associated with treatment response in childhood acute lymphoblastic leukemia.
|
JAMA
|
2009
|
2.72
|
|
11
|
A clinically relevant population of leukemic CD34(+)CD38(-) cells in acute myeloid leukemia.
|
Blood
|
2012
|
2.65
|
|
12
|
Outcome modeling with CRLF2, IKZF1, JAK, and minimal residual disease in pediatric acute lymphoblastic leukemia: a Children's Oncology Group study.
|
Blood
|
2012
|
2.09
|
|
13
|
Effectiveness of high-dose methotrexate in T-cell lymphoblastic leukemia and advanced-stage lymphoblastic lymphoma: a randomized study by the Children's Oncology Group (POG 9404).
|
Blood
|
2011
|
2.04
|
|
14
|
Genome-wide association study identifies germline polymorphisms associated with relapse of childhood acute lymphoblastic leukemia.
|
Blood
|
2012
|
1.90
|
|
15
|
Reinduction platform for children with first marrow relapse of acute lymphoblastic Leukemia: A Children's Oncology Group Study[corrected].
|
J Clin Oncol
|
2008
|
1.83
|
|
16
|
Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: a Children's Oncology Group Pilot Study.
|
J Clin Oncol
|
2008
|
1.75
|
|
17
|
Biologic pathways associated with relapse in childhood acute lymphoblastic leukemia: a Children's Oncology Group study.
|
Blood
|
2006
|
1.74
|
|
18
|
Down syndrome childhood acute lymphoblastic leukemia has a unique spectrum of sentinel cytogenetic lesions that influences treatment outcome: a report from the Children's Oncology Group.
|
Blood
|
2010
|
1.67
|
|
19
|
Aberrant STAT5 and PI3K/mTOR pathway signaling occurs in human CRLF2-rearranged B-precursor acute lymphoblastic leukemia.
|
Blood
|
2012
|
1.66
|
|
20
|
Brief intensive therapy for older adults with newly diagnosed Burkitt or atypical Burkitt lymphoma/leukemia.
|
Leuk Lymphoma
|
2012
|
1.57
|
|
21
|
Tyrosine kinome sequencing of pediatric acute lymphoblastic leukemia: a report from the Children's Oncology Group TARGET Project.
|
Blood
|
2012
|
1.47
|
|
22
|
Inherited GATA3 variants are associated with Ph-like childhood acute lymphoblastic leukemia and risk of relapse.
|
Nat Genet
|
2013
|
1.45
|
|
23
|
Detection of paroxysmal nocturnal hemoglobinuria clones to exclude inherited bone marrow failure syndromes.
|
Eur J Haematol
|
2014
|
1.41
|
|
24
|
Inactivation of LEF1 in T-cell acute lymphoblastic leukemia.
|
Blood
|
2010
|
1.40
|
|
25
|
Augmented therapy improves outcome for pediatric high risk acute lymphocytic leukemia: results of Children's Oncology Group trial P9906.
|
Pediatr Blood Cancer
|
2011
|
1.33
|
|
26
|
NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on Disease-Specific Methods and Strategies for Monitoring Relapse following Allogeneic Stem Cell Transplantation. Part I: Methods, acute leukemias, and myelodysplastic syndromes.
|
Biol Blood Marrow Transplant
|
2010
|
1.23
|
|
27
|
Immature granulocyte measurement using the Sysmex XE-2100. Relationship to infection and sepsis.
|
Am J Clin Pathol
|
2003
|
1.21
|
|
28
|
Pilot study of nelarabine in combination with intensive chemotherapy in high-risk T-cell acute lymphoblastic leukemia: a report from the Children's Oncology Group.
|
J Clin Oncol
|
2012
|
1.20
|
|
29
|
Absence of biallelic TCRgamma deletion predicts early treatment failure in pediatric T-cell acute lymphoblastic leukemia.
|
J Clin Oncol
|
2010
|
1.14
|
|
30
|
Knock-in of a FLT3/ITD mutation cooperates with a NUP98-HOXD13 fusion to generate acute myeloid leukemia in a mouse model.
|
Blood
|
2012
|
1.14
|
|
31
|
Phase 2 trial of clofarabine in combination with etoposide and cyclophosphamide in pediatric patients with refractory or relapsed acute lymphoblastic leukemia.
|
Blood
|
2011
|
1.12
|
|
32
|
Phase II study of risk-adapted therapy of newly diagnosed, aggressive non-Hodgkin lymphoma based on midtreatment FDG-PET scanning.
|
Biol Blood Marrow Transplant
|
2009
|
1.10
|
|
33
|
Intrachromosomal amplification of chromosome 21 is associated with inferior outcomes in children with acute lymphoblastic leukemia treated in contemporary standard-risk children's oncology group studies: a report from the children's oncology group.
|
J Clin Oncol
|
2013
|
1.07
|
|
34
|
Pharmacogenetics of minimal residual disease response in children with B-precursor acute lymphoblastic leukemia: a report from the Children's Oncology Group.
|
Blood
|
2008
|
1.05
|
|
35
|
FLT3 mutations in myeloid sarcoma.
|
Br J Haematol
|
2004
|
0.95
|
|
36
|
Outcomes of autologous and allogeneic blood or marrow transplantation for mantle cell lymphoma.
|
Biol Blood Marrow Transplant
|
2005
|
0.94
|
|
37
|
Clinical and pathologic features of secondary acute promyelocytic leukemia.
|
Am J Clin Pathol
|
2012
|
0.93
|
|
38
|
A clinical evaluation of high fluorescent platelet fraction percentage in thrombocytopenia.
|
Am J Clin Pathol
|
2006
|
0.92
|
|
39
|
High-dose therapy and blood or marrow transplantation for non-Hodgkin lymphoma with central nervous system involvement.
|
Biol Blood Marrow Transplant
|
2005
|
0.91
|
|
40
|
NCI first international workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: report from the committee on disease-specific methods and strategies for monitoring relapse following allogeneic stem cell transplantation. part II: chronic leukemias, myeloproliferative neoplasms, and lymphoid malignancies.
|
Biol Blood Marrow Transplant
|
2010
|
0.91
|
|
41
|
Lack of surface immunoglobulin light chain expression by flow cytometric immunophenotyping can help diagnose peripheral B-cell lymphoma.
|
Am J Clin Pathol
|
2002
|
0.90
|
|
42
|
Inter- and intra-observer reliability of Epstein-Barr virus detection in Hodgkin lymphoma using histochemical procedures.
|
Leuk Lymphoma
|
2004
|
0.86
|
|
43
|
Simplified flow cytometric assessment in mycosis fungoides and Sézary syndrome.
|
Am J Clin Pathol
|
2011
|
0.85
|
|
44
|
Flow cytometric findings in hemophagocytic lymphohistiocytosis.
|
Am J Clin Pathol
|
2012
|
0.85
|
|
45
|
Hematological manifestations of nephropathic cystinosis.
|
Acta Haematol
|
2008
|
0.82
|
|
46
|
Toxicity assessment of molecularly targeted drugs incorporated into multiagent chemotherapy regimens for pediatric acute lymphocytic leukemia (ALL): review from an international consensus conference.
|
Pediatr Blood Cancer
|
2010
|
0.82
|
|
47
|
The usefulness of CD71 expression by flow cytometry for differentiating indolent from aggressive CD10+ B-cell lymphomas.
|
Am J Clin Pathol
|
2006
|
0.82
|
|
48
|
Targeted pathologic evaluation of bone marrow donors identifies previously undiagnosed marrow abnormalities.
|
Biol Blood Marrow Transplant
|
2013
|
0.81
|
|
49
|
HHV-8-positive and EBV-positive intravascular lymphoma: an unusual presentation of extracavitary primary effusion lymphoma.
|
Am J Surg Pathol
|
2014
|
0.80
|
|
50
|
Overexpression of CD49f in precursor B-cell acute lymphoblastic leukemia: potential usefulness in minimal residual disease detection.
|
Cytometry B Clin Cytom
|
2009
|
0.80
|
|
51
|
Software-automated counting of Ki-67 proliferation index correlates with pathologic grade and disease progression of follicular lymphomas.
|
Am J Clin Pathol
|
2013
|
0.76
|
|
52
|
A Pilot Study of Intensified PEG-Asparaginase in High-risk Acute Lymphoblastic Leukemia: Children's Oncology Group Study AALL08P1.
|
J Pediatr Hematol Oncol
|
2016
|
0.75
|
|
53
|
Flow cytometry of lesional skin enhances the evaluation of cutaneous B-cell lymphomas.
|
J Cutan Pathol
|
2012
|
0.75
|
|
54
|
Primary effusion lymphoma presenting as a cutaneous intravascular lymphoma.
|
J Cutan Pathol
|
2014
|
0.75
|
|
55
|
Lymphadenopathy as the primary manifestation of malignant transformation in two patients with severe congenital neutropenia.
|
Pediatr Blood Cancer
|
2008
|
0.75
|
|
56
|
Initial Diagnostic Workup of Acute Leukemia: Guideline From the College of American Pathologists and the American Society of Hematology.
|
Arch Pathol Lab Med
|
2017
|
0.75
|
|
57
|
Resolution of ambiguous low-level positive quantitative polymerase chain reaction results in TEL-AML1 positive ALL using a post-PCR fluorescent oligoligation method.
|
Br J Haematol
|
2006
|
0.75
|